ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0239

Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019

Elaine Husni1, Steven Peterson2, Natalie Dennis3, Feifei Yang4, Iris Lin4, Yiting Wang5, Soumya Chakravarty6, Claire Fischer3, May Shawi7, Arthur Quenéchdu3 and Joseph Merola8, 1Cleveland Clinic, Cleveland, OH, 2Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, 3Amaris, Health Economics and Market Access, Paris, France, 4Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, 5Janssen R&D, LLC, Titusville, NJ, 6Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 7Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 8Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Economics, Fatigue, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to be associated with both short-term and long-term work absences. The objective of this study was to evaluate the impact of fatigue on short-term disability among patients with PsA in the United States.

Methods: Adults eligible for short-term disability benefits between 2009 and 2019 were screened in the IBM® MarketScan® Commercial and Health and Productivity Management Databases. Patients with ≥ 2 diagnoses for PsA ≥ 30 days apart were included. Patients with fatigue (i.e., cases) had ≥ 1 fatigue diagnosis after their initial PsA diagnosis, and the first fatigue diagnosis was defined as the index date. Controls were PsA patients who had no fatigue diagnoses during the study period; their index date was defined using the cases’ median time from initial PsA to the first fatigue diagnosis. Patients had continuous enrollment from ≥ 6 months before their initial PsA diagnosis (baseline period) to ≥ 12 months after the index date (follow-up period) and had to be eligible for short-term disability benefits during the entire follow-up period. Patients with rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, or ulcerative colitis during the study period were excluded from the analyses. Controls were matched 1:1 to cases based on propensity scores that balanced age, gender, year of initial PsA diagnosis, PsA treatment, related conditions, the Charlson Comorbidity Index, variables associated with PsA disease severity, vitamin D deficiency, and common infections (Table 1). Change in short-term disability and associated costs (in 2019 USD) were calculated from baseline through follow-up.

Results: 1,244 patients with fatigue were matched to the control group (Table 1). The average age at baseline was 46.3 years and 43.0% were female. Patients with PsA and fatigue missed an average of 6.9 days due to short-term disability, whereas controls missed an average of 3.4 days (p=0.0013, Table 2). Average costs associated with short-term disability were $438 and $897 for controls and PsA patients with fatigue, respectively (p=0.0011). During follow-up, 6.6% of patients in the control group had at least one short-term disability leave compared to 10.2% of patients with fatigue (p=0.0014).

Conclusion: Higher rates of annual short-term disability were observed among patients with PsA and fatigue than without fatigue. These results highlight the substantial indirect costs and economic burden of fatigue in patients with PsA.

Table 1. Baseline characteristics before and after matching (1)

(1) Variables were evaluated during the 6-month baseline period

(2) Variables in italic were not included in the matching

Table 2. Short-term disability outcomes during follow-up


Disclosures: E. Husni, AbbVie, 2, Amgen, 2, Janssen, 2, Novartis, 2, Eli Lilly, 2, UCB, 2, Regeneron, 2; S. Peterson, Janssen, 3, 11; N. Dennis, None; F. Yang, Janssen Research & Development, LLC (a subsidiary of Johnson & Johnson), 3, 11; I. Lin, Janssen Scientific Affairs, LLC, 3, Johnson & Johnson, 3, 11; Y. Wang, Janssen, 3; S. Chakravarty, Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), 3, 11; C. Fischer, None; M. Shawi, Janssen Global Services, LLC (a subsidiary of Johnson & Johnson), 3, 11; A. Quenéchdu, None; J. Merola, Dermavant, 5, LEO Pharma, 3, Abbvie, 2, Amgen, 2, Bayer, 2, Eli Lilly, 2, Novartis, 2, Janssen, 2, UCB, 2, 5, Celgene, 2, Sanofi-Regeneron, 2, Biogen, 2, Pfizer, 2, BMS, 2.

To cite this abstract in AMA style:

Husni E, Peterson S, Dennis N, Yang F, Lin I, Wang Y, Chakravarty S, Fischer C, Shawi M, Quenéchdu A, Merola J. Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/work-disability-associated-with-fatigue-in-patients-with-psoriatic-arthritis-a-retrospective-study-using-claims-data-2009-2019/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/work-disability-associated-with-fatigue-in-patients-with-psoriatic-arthritis-a-retrospective-study-using-claims-data-2009-2019/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology